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ABSTRACT
Oncogenic osteomalacia is a rare metabolic bone 
disease characterized by phosphate leakage from 
the kidney and subsequent hypophosphatemia. It is 
caused by a phosphaturic factor produced by certain 
tumours. removal of such tumours can completely 
cure the condition. Here, we report the case of a pa-
tient who was crippled with oncogenic osteomalacia. 
Extensive study revealed a tumour deeply located in 
the pelvis; removal of the tumour resulted in complete 
recovery. The tumour was identified as a mesenchy-
mal tumour (mixed connective-tissue variant). The 
diagnostic evaluation, differential diagnosis, and 
treatment are discussed.
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1.  INTRODUCTION
Tumour-induced osteomalacia 1, also known as 
oncogenic osteomalacia 2, is an acquired disorder 
that results in markedly deranged mineral and 
skeletal metabolism. The disorder is characterized 
by hypophosphatemia (because of renal phosphate 
wasting), osteomalacia, bone pain, proximal muscle 
weakness, fractures, and functional disability 3. a 
reduction in circulating 1,25(OH)2-vitamin d despite 
hypophosphatemia is the biochemical hallmark of 
the disease 4,5. In this disorder, osteomalacia mimics 
the clinical phenotype of either X-linked (x l h r ) or 
autosomal-dominant hereditary hypophosphatemic 
rickets (a d h r ) 5–8.
Oncogenic osteomalacia is commonly associated 
with small, slow-growing tumours of mesenchymal 
origin that may be difficult to detect 4,5,9. The tumours 
were first reported by McCance in 1947 10, and the 
association between those tumours and osteomalacia 
was reported in 1959 by Prader and coworkers 11. 
Normalization of serum phosphate and remission 
of the bone disease can be achieved if the causative 
tumour is located and completely removed 3,5.
Here, we report a case of oncogenic osteomalacia 
in a 39-year-old man with a mesenchymal tumour in 
the pelvis. removal of the tumour resulted in reversal 
of all the biochemical abnormalities and disappear-
ance of the clinical manifestations.
2.  CASE REPORT
a 39-year-old man was referred from the orthopedic 
clinic to the endocrine clinic for re-evaluation because 
of suspected metabolic bone disease. His illness had 
started 3 years earlier, when he complained of low 
back pain that was progressive and associated with 
pain in the lower limbs and shoulders. a few months 
later, he developed limping on the left leg. Initially, 
a lumbar disease was suspected, but magnetic reso-
nance imaging (m r i ) of the area was negative for disc 
prolapse. The patient was treated symptomatically 
with painkillers. later, he complained of diffuse bone 
pain, accompanied by generalized muscle weakness, 
which led to severe debilitation. He had difficulty 
walking and standing from a sitting position. There 
was no family history of a similar condition.
Clinical physical examination revealed severe 
proximal muscle weakness and waddling gait. Heart, 
chest, and abdominal examinations were within 
norms, and no abnormalities were detected. Complete 
blood count was normal.
Biochemical evaluation revealed persistent hy-
pophosphatemia 0.6 mmol/L (normal range: 0.81–
1.6 mmol/L). Multiple determinations of serum calcium 
were normal: 2.1, 2.2, and 2.3 mmol/L (normal range: 
2.0–2.6 mmol/L), but serum alkaline phosphatase was 
839, 1910, 2093 IU/L (normal range: 100–290 IU/L). 
Urea at 6 mmol/l, creatinine at 60 mmol/l, and   88
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sodium and potassium levels were normal. Parathyroid 
hormone (p t h) was 50 pg/mL (normal range: 7–53 pg/
mL). Serum 25-hydroxycholecalciferol was 19 ng/L 
(normal range: 8.9–46.7 ng/L) and 1,25(OH)2-
cholecalciferol was low-normal at 48 pmol/L (normal 
range: 48–110 pmol/L). Serum protein electrophoresis 
and thyroid function tests were normal. The patient’s 
urine was negative for protein and glucose, and no 
metabolic acidosis was present. Urinary inorganic 
phosphorus excretion was 18.5 mmol/24 h (normal: 
<32.3 mmol/24 h), calcium was 4 mmol/24 h (nor-
mal range: 2.5–7.5 mmol/24 h), and creatinine was 
20 mmol/24 h (normal range: 7.5–17.7 mmol/24 h). 
The maximal rate of renal tubular reabsorption 
of phosphate to the glomerular filtration rate was 
1.84 mg/dL (normal range: 2.3–4.3 mg/dL) 12–14.
roentgenologic examination revealed generalized 
osteopenia. a three-phase 99Tc bone scan revealed a 
generalized increase in osteoblastic activity in the 
bony skeleton with decreased renal activity. This 
pattern is known as a “superscan,” which is usually 
seen in metabolic bone diseases, including primary 
and secondary hyperparathyroidism. an increase 
in focal activity was observed in the left calcaneus, 
mostly because of overuse, and in the patella of the 
left knee. Because of these clinical, biochemical, and 
Roentgenologic findings, oncogenic osteomalacia 
was suspected.
Computed tomography (c t ) imaging of the neck, 
chest, left calcaneus, and right patella showed no soft-
tissue masses to indicate the possible location of the tu-
mour. abdominal, renal, and pelvic c t  imaging showed 
right middle calyceal or parenchymal calcifications. A 
well-defined enhancing soft-tissue-mass lesion meas-
uring 5×1.2×1 cm was seen medially to the left psoas 
muscle at the level of lumbar vertebra 4 (L4). This mass 
contained fatty components and appeared adherent to 
the left transverse process of L4 (Figure 1).
The tumour was resected on January 13, 2005, at 
Jordan University Hospital. Histologic examination 
showed an unencapsulated tumour with a variegated 
microscopic appearance, composed of a mixture of 
benign mesenchymal cells (Figure 2). Those cells 
were admixed with wider areas showing prominent 
chondroid differentiation. Islands of mature adipose 
tissue were also identified, as was a foci of osteoid-
like matrix. The tumour contained a prominent mi-
crovasculature ranging from purely capillary-sized 
vessels to thicker, hyalinized ones, some of which 
resembled an aneurismal bone-cyst-like pattern. No 
evidence of malignancy was found. The pathologic 
diagnosis was a mesenchymal tumour (mixed connec-
tive-tissue variant), completely excised (5×5 cm) with 
no evidence of involvement in the excised 3 adjacent 
aortic lymph nodes.
Three months after surgery, the patient was 
asymptomatic. His weakness improved, his phos-
phate was normal (0.82 mmol/L), and only a 
slightly elevated alkaline phosphatase was recorded 
(300 IU/L). Eighteen months later, the patient was 
re-evaluated. There were no complaints, and all 
laboratory investigations showed values within 
normal ranges. another re-evaluation, 3 years after 
removal of the tumour, revealed no symptoms or 
complaints. laboratory investigations at that time 
were also normal.
3.  DISCUSSION
The insidious development of progressive bone pain 
and muscle weakness is a well known feature of 
osteomalacia, which may have many causes 15. di-
agnostic difficulties are particularly encountered in 
acquired hypophosphatemia, a condition associated 
with increased renal clearance and lower circulating 
1,25(OH)2-cholecalciferol 4,5, especially when there is 
no family history of osteomalacia or rickets. Tumour-
induced oncogenic osteomalacia is a rare acquired 
condition of metabolic bone disease, in which phos-
phate metabolism is markedly deranged 1,3.
To date, more than 160 cases of oncogenic os-
teomalacia have been reported in the literature 2,16. 
These tumours are usually mesenchymal or mixed 
connective tissue, arising from a wide range of tis-
sues, chiefly in the head and neck, and less frequently 
in bones and other tissues. They are usually benign 
in nature. Even in histologically malignant tumours, 
either local recurrence or distant metastasis is ex-
tremely rare 17. The most common types are vascular 
neoplasms (hemangiopericytomas). Other types 
include fibromas, chondrosarcomas, histiocytomas, 
neuroblastomas, and prostate carcinoma 2,4,5,9,18.
The clinical signs and symptoms of oncogenic 
osteomalacia as a neoplastic syndrome are nonspe-
cific and often lead to erroneous diagnosis of joint, 
muscle, or neurologic disorders. Most patients report 
bone or muscle tenderness and weakness. Our patient 
f i g u r e  1  Computerized tomography image showing a well-defined 
(5×1.2×1-cm) enhancing soft-tissue lesion located medially of the 
left psoas muscle at the level of lumbar vertebra 4.89
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complained of diffuse progressive bone pain over 
3 years and had difficulty walking.
The biochemical markers of oncogenic osteoma-
lacia include hypophosphatemia, hyperphosphaturia, 
decreased tubular phosphate reabsorption, increased 
serum alkaline phosphatase in the presence of normal 
calcium, 25(OH) vitamin D, and normal or slightly 
elevated serum p t h  5. Selective low and low-to-normal 
1,25(OH)2 vitamin d and hypophosphatemia are 
biochemical features also seen in a d h r  and x l h r  5, in 
which they present a lifelong clinical and biochemical 
picture. The management of these two conditions is 
different, with the clinical picture in the current case 
resolving after removal of the phosphaturic mesen-
chymal tumour, mixed connective-tissue variant 2, 
which may indicate involvement of the phosphate-
regulating pathway 5.
In the current case, as in others previously de-
scribed, not all biochemical markers were present 5. 
The late presentation and absence of family history, 
together with cure after surgery, made a diagnosis of 
a d h r  or x l h r  unlikely in our patient. There was no 
role for adjuvant therapy. Treatment with large doses 
of neutral phosphate presents great risk for the devel-
opment of tertiary hyperparathyroidism in oncogenic 
osteomalacia 4. detection of the tumour responsible 
therefore held great clinical importance. Because 
these tumours are usually small in size, they are dif-
ficult to identify. In our patient, the tumour was found 
after almost total body c t  imaging and was confirmed 
by m r i . Similar diagnostic procedures, and other new-
er techniques such as combined positron-emission 
tomography–c t , are used to detect these tumours 19. 
In our patient, the tumour was located deep in the 
pelvis in a very unusual location—a location that, to 
our knowledge, has not previously been described 2. 
The tumour was a phosphaturic mesenchymal tumour, 
mixed connective-tissue variant type, as are 80% of 
such tumours 2. The complete resolution of the clini-
cal and biochemical abnormalities after removal of 
the tumour indicates that it was the source of the 
hormonal factor that inhibited Na–P co-transport in 
renal proximal tubular cells and lowered 1,25(OH)2 
vitamin d production 1,4.
Patients with oncogenic osteomalacia have been 
found to have high serum levels of fibroblast growth 
factor 23 (f g f 23). Evaluation of this substance and 
of the phosphate-regulating gene with homologies 
to endopeptidase on the X chromosome (PHEX), 
whose loss of function causes a d h r  and whose mu-
tation causes x l h r , may provide diagnostic clues 
(Table i) 4,5,20. Unfortunately, f g f 23 and PHEX were 
not evaluated because of an impossibility of perform-
ing immunohistochemistry at the time.
f i g u r e  2  Photomicrograph of the excised mixed connective tissue (mesenchymal tumour), showing (A) plasma cells; (B) chondroid-like 
material; (C) plasma cells, chondroid-like material, and capillaries.
t a b l e  i  Hypophosphatemic conditions caused by excess action of fibroblast growth factor 23 (f g f 23) and causes of excess f g f 23 action
  Disease  Causes of excess f g f 23 action
autosomal dominant hypophosphatemic rickets or osteomalacia  dysregulated f g f 23 expression because of mutations in the 
  f g f 23 gene
  Overexpression of f g f 23 in bone because of mutations in the  
  d m p 1 gene
X-linked hypophosphatemic rickets or osteomalacia  Overexpression of f g f 23 in bone because of mutations in p e h x   
  gene
McCune–Albright syndrome and fibrous dysplasia  Overexpression of f g f 23 in bone
Tumour-induced rickets or osteomalacia  Overexpression of f g f 23 in the responsible tumour
d m p 1  = dentin matrix acidic phosphoprotein 1; p h e x = phosphate-regulating endopeptidase homolog, X chromosome–linked.90
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4.  CONCLUSIONS
For the first time in Jordan, we describe a patient with 
oncogenic osteomalacia, stemming from an unusually 
deeply located mesenchymal tumour in the pelvis. 
Complete reversal of the clinical and biochemical 
manifestations was achieved after removal of the tu-
mour. For patients who have a clinical and biochemi-
cal picture suggestive of oncogenic osteomalacia, it is 
of crucial importance to perform a meticulous survey 
to detect the tumour or tumours responsible.
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